BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38179984)

  • 1. Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy.
    Jahncke JN; Miller DS; Krush M; Schnell E; Wright KM
    Elife; 2024 Jan; 12():. PubMed ID: 38179984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal Dystroglycan Is Necessary for Formation and Maintenance of Functional CCK-Positive Basket Cell Terminals on Pyramidal Cells.
    Früh S; Romanos J; Panzanelli P; Bürgisser D; Tyagarajan SK; Campbell KP; Santello M; Fritschy JM
    J Neurosci; 2016 Oct; 36(40):10296-10313. PubMed ID: 27707967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The many roles of dystroglycan in nervous system development and function: Dystroglycan and neural circuit development: Dystroglycan and neural circuit development.
    Jahncke JN; Wright KM
    Dev Dyn; 2023 Jan; 252(1):61-80. PubMed ID: 35770940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal Dystroglycan regulates postnatal development of CCK/cannabinoid receptor-1 interneurons.
    Miller DS; Wright KM
    Neural Dev; 2021 Aug; 16(1):4. PubMed ID: 34362433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD+ improves neuromuscular development in a zebrafish model of FKRP-associated dystroglycanopathy.
    Bailey EC; Alrowaished SS; Kilroy EA; Crooks ES; Drinkert DM; Karunasiri CM; Belanger JJ; Khalil A; Kelley JB; Henry CA
    Skelet Muscle; 2019 Aug; 9(1):21. PubMed ID: 31391079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
    Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
    J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
    Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
    Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes.
    Karas BF; Terez KR; Mowla S; Battula N; Flannery KP; Gural BM; Aboussleman G; Mubin N; Manzini MC
    Hum Mol Genet; 2024 Apr; 33(8):709-723. PubMed ID: 38272461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice.
    Foltz SJ; Modi JN; Melick GA; Abousaud MI; Luan J; Fortunato MJ; Beedle AM
    PLoS One; 2016; 11(1):e0147049. PubMed ID: 26751696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystroglycan Maintains Inner Limiting Membrane Integrity to Coordinate Retinal Development.
    Clements R; Turk R; Campbell KP; Wright KM
    J Neurosci; 2017 Aug; 37(35):8559-8574. PubMed ID: 28760865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy.
    Dai Y; Liang S; Dong X; Zhao Y; Ren H; Guan Y; Yin H; Li C; Chen L; Cui L; Banerjee S
    J Cell Mol Med; 2019 Feb; 23(2):811-818. PubMed ID: 30450679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.
    Martin PT; Shelton GD; Dickinson PJ; Sturges BK; Xu R; LeCouteur RA; Guo LT; Grahn RA; Lo HP; North KN; Malik R; Engvall E; Lyons LA
    Neuromuscul Disord; 2008 Dec; 18(12):942-52. PubMed ID: 18990577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.
    Muntoni F; Torelli S; Wells DJ; Brown SC
    Curr Opin Neurol; 2011 Oct; 24(5):437-42. PubMed ID: 21825985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fourth case of POMT2-related limb girdle muscle dystrophy with mild reduction of α-dystroglycan glycosylation.
    Saredi S; Gibertini S; Ardissone A; Fusco I; Zanotti S; Blasevich F; Morandi L; Moroni I; Mora M
    Eur J Paediatr Neurol; 2014 May; 18(3):404-8. PubMed ID: 24183756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods.
    Kanagawa M
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial scaffold required for cerebellar granule cell migration is dependent on dystroglycan function as a receptor for basement membrane proteins.
    Nguyen H; Ostendorf AP; Satz JS; Westra S; Ross-Barta SE; Campbell KP; Moore SA
    Acta Neuropathol Commun; 2013 Sep; 1():58. PubMed ID: 24252195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
    Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
    Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAG1 mutations associated with asymptomatic hyperCKemia and hypoglycosylation of α-dystroglycan.
    Dong M; Noguchi S; Endo Y; Hayashi YK; Yoshida S; Nonaka I; Nishino I
    Neurology; 2015 Jan; 84(3):273-9. PubMed ID: 25503980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.